Media registration for 22nd EORTC-NCI-AACR Symposium
Understanding the pathways and mechanisms that cause cancer and regulate the biological behaviour of tumour cells has led to the development of numerous new agents, 'designer' diagnostics, prognostic tests, 'smart' drugs, innovative targets for clinical trials and other entirely new ways of tackling cancer.
To bring these developments to patients as quickly and efficiently as possible requires international collaboration, early and optimal exchange of information, good quality translational research, efficient drug development and large prospective clinical trials.
At this Symposium, three of the world's leading cancer organisations:
- The European Organisation for Research and Treatment of Cancer
- The USA's National Cancer Institute
- The American Association for Cancer Research
will join forces in Berlin on 16-19 November to provide a platform for presenting the recent advances in the early development of promising new compounds in different stages of pre-clinical and clinical research to around 2,200 international experts in the field, igniting a vast exchange of information whilst promoting and developing global partnerships in translational research.
We welcome the media to the Symposium. Every session is open to journalists and registration is free to bona fide media presenting official press credentials, or a letter on headed paper from the editor of the journal/website they represent stating that they are being commissioned to write a report for publication. Copies of the credentials and identification will be requested at the time of registration and when journalists arrive at the Symposium. Business cards are NOT acceptable.
A media centre with computers, international phone and internet connections will be available.
Provided by ECCO-the European CanCer Organisation
